Anondita Medicare Ltd
Founded in March 2024, Anondita Medicare Limited manufactures flavored male condoms, with its flagship product branded as “COBRA.”[1]
- Market Cap ₹ 1,995 Cr.
- Current Price ₹ 1,103
- High / Low ₹ 1,227 / 262
- Stock P/E 74.4
- Book Value ₹ 62.5
- Dividend Yield 0.00 %
- ROCE 39.6 %
- ROE 37.9 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 44.3%
Cons
- Stock is trading at 17.6 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Fast Moving Consumer Goods Fast Moving Consumer Goods Personal Products Personal Care
Part of Nifty SME Emerge
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2024 1m | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| 0 | 61 | 112 | |
| 0 | 43 | 72 | |
| Operating Profit | 0 | 18 | 39 |
| OPM % | 30% | 35% | |
| 0 | 0 | 2 | |
| Interest | 0 | 3 | 3 |
| Depreciation | 0 | 1 | 1 |
| Profit before tax | 0 | 14 | 37 |
| Tax % | 25% | 27% | |
| 0 | 11 | 27 | |
| EPS in Rs | 0.00 | 8.12 | 14.83 |
| Dividend Payout % | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 85% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 148% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 44% |
| Last Year: | 38% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 0.10 | 13 | 18 |
| Reserves | 0 | 15 | 95 |
| 0 | 27 | 33 | |
| 0 | 9 | 17 | |
| Total Liabilities | 0 | 64 | 163 |
| 0 | 13 | 81 | |
| CWIP | 0 | 6 | 0 |
| Investments | 0 | 4 | 4 |
| 0 | 41 | 79 | |
| Total Assets | 0 | 64 | 163 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| -0 | 6 | 4 | |
| 0 | -23 | -61 | |
| 0 | 17 | 67 | |
| Net Cash Flow | 0 | 0 | 9 |
| Free Cash Flow | -0 | -14 | -59 |
| CFO/OP | 36% | 18% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor Days | 100 | 124 | |
| Inventory Days | 115 | 101 | |
| Days Payable | 45 | 59 | |
| Cash Conversion Cycle | 170 | 166 | |
| Working Capital Days | 101 | 140 | |
| ROCE % | 62% | 40% |
Insights
In beta| Jan 2026 | Mar 2027 (P) | |
|---|---|---|
| Installed Manufacturing Capacity million pieces per annum |
|
|
| Capacity Under Trial Production million pieces per annum |
||
| Existing Capacity Utilization million pieces per annum |
||
| Existing Capacity Utilization (%) % |
||
| IPO Proceeds Re-allocation to Working Capital INR Lakhs |
||
| IPO Proceeds Utilized (Total) INR Lakhs |
||
| IPO Unutilized Amount INR Lakhs |
||
| L1 GeM Tender Supply Volume (Condoms) pieces |
||
| L1 GeM Tender Supply Volume (Family Planning Items) pieces |
||
| Order Value (CMSS GeM Tender) INR |
||
| Projected Turnover for FY2025-26 INR Crores |
||
| Target Capacity Expansion (Noida Facility) million pieces per annum |
||
Extracted by Screener AI
Documents
Announcements
-
Corrigendum
23 May 2026 - Second corrigendum to 28 May 2026 EGM notice revises valuation report and PCS certificate for preferential issue at ₹1,038.
-
Integrated Filing- Financial
22 May 2026 - Anondita Medicare reported FY26 audited consolidated revenue of 13,741.57 lakh and net profit of 3,429.65 lakh.
-
Outcome of Board Meeting
22 May 2026 - Anondita Medicare announced audited standalone and consolidated results for year ended March 31, 2026.
-
Updates
22 May 2026 - Board approved audited FY2026 results; standalone revenue rose to Rs 11,160.62 lakh, profit to Rs 2,682.07 lakh.
-
Statement of deviation(s) or variation(s) under Reg. 32
22 May 2026 - Anondita Medicare Limited has informed about statement of deviation(s) or variation(s) under Reg. 32
Annual reports
No data available.
Concalls
-
Mar 2026TranscriptAI SummaryPPT
Business Profile:[1]
Anondita Medicare manufactures male (and recently, female) condoms, flagship brand “COBRA,” with in-house printing/packaging and 100% electronic testing.